Preclinical Alzheimer’s unlikely to lead to dementia, new study reports

1200 829 Peter Stevenson, PhD

New data from a multi-study analysis has unveiled that preclinical Alzheimer’s disease (AD) will not lead to severe dementia in the majority of cases. The paper marks the first time…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more

Machine learning offers automated diagnosis in stroke and dementia

1200 800 Peter Stevenson, PhD

Researchers have harnessed the power of artificial intelligence (AI) to identify a key cause of dementia and stroke – and with stunning accuracy – a new study reports. Created by…

read more

“Ask the audience”: Stroke debates feature at ESOC 2018

1600 2400 Peter Stevenson, PhD

Controversies in stroke were laid bare at the recent European Stroke Organisation Conference (ESOC) in Gothenburg, Sweden, in a special session that saw experts rallying to convince the audience of…

read more

First MS treatment approved for children & adolescents

1600 1067 Peter Stevenson, PhD

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

read more

​Saunas linked to reduced stroke risk

1200 800 Peter Stevenson, PhD

Regular use of saunas could be key in reducing stroke risk, a new European study reports. Baseline sauna habits of 1,628 men and women (age 53–74 years; mean 62.7) without prior…

read more

Start MS drugs early, say new guidelines​

1400 885 Peter Stevenson, PhD

Drug therapy for multiple sclerosis (MS) should be started early, according to updated guidelines from the American Academy of Neurology (AAN), which were presented at the recent AAN annual meeting…

read more

Solriamfetol improves wakefulness in narcolepsy patients

1920 1280 Lutz Achtnichts, MD

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

read more

​Huntington’s disease: Antisense drug showing promising results

4288 3216 Lutz Achtnichts, MD

Results from a Phase I/IIa study of IONIS-HTTRx (RG6042) in Huntington’s disease (HD) were presented in a plenary session at the 2018 annual meeting of the American Academy of Neurology (AAN). Results…

read more

​Promising new migraine treatment presented at AAN 2018

5184 3456 Lutz Achtnichts, MD

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…

read more
Brainwork is supported by unrestricted grants from: